MDT Q3 2026 Earnings Call Summary

Medtronic Q3 2026 Earnings Call Summary

1. Key Financial Results and Metrics

Revenue: $9 billion, representing an 8.7% reported growth and 6% organic growth, a 50 basis point acceleration from the previous quarter.
Adjusted EPS: $1.36, exceeding guidance by $0.03.
Adjusted Gross Margin: 64.9%, ahead of expectations.
Adjusted Operating Profit: $2.2 billion, with an operating margin of 24.1%.
Geographic Growth: High single-digit growth in Western Europe, mid-single-digit growth in the U.S. (6% year-over-year), and low single-digit growth in China.

2. Strategic Updates and Business Highlights

Cardiovascular Portfolio: 11% year-over-year growth, with 80% growth in Cardiac Ablation Solutions (CAS), driven by the PFA platform.
Key Growth Drivers:
- PFA Platform: Nearly 200% growth, gaining 4 points of market share in a $13 billion market.
- Symplicity Spyral: Strong patient outcomes and a direct-to-consumer campaign led to a 50x increase in website visits.
- Altaviva: Early interest in this urinary incontinence treatment.
- Hugo Surgical Robot: Received FDA clearance for urologic procedures, with initial installations completed.
- Stealth AXiS: New AI-powered surgical system for spinal procedures received FDA clearance, expected to enhance growth in Neuroscience.
M&A Activity: Recent acquisitions include CathWorks and Anteris, focusing on tuck-in deals to enhance growth in core markets.

3. Forward Guidance and Outlook

Fiscal 2026 Guidance: Reiterating organic revenue growth of approximately 5.5% for the full year, with Q4 expected to mirror Q3's growth rate.
EPS Guidance: Maintaining guidance in the range of $5.62 to $5.66, with expectations for high single-digit growth in FY '27.
Gross Margin Outlook: Slight increase expected in fiscal '26, despite tariff impacts.

4. Challenges and Points of Concern

Structural Heart Business: Softer growth in Q3, with competitive pressures noted in the U.S. market.
Neuroscience Portfolio: Growth below expectations, although a strong pipeline is anticipated to impact future results.
Tariff Impacts: Expected to affect gross margins, with a projected $185 million impact for fiscal '26.
Market Development: The need for ongoing investment in hiring and training for new product launches, particularly in renal denervation and catheter use.

5. Notable Q&A Insights

CAS Growth Sustainability: While CAS has shown strong growth, maintaining this momentum may be challenging as it begins to lap previous launches.
Market Development for RDN: Significant consumer interest and physician engagement are noted, with a focus on building referral networks and enhancing market presence.
Hugo's Impact: Although initial installations are promising, it may take time to significantly impact the overall Surgical business.
Capital Allocation Strategy: Emphasis on tuck-in acquisitions and investments in high-growth areas, with a cautious approach to larger deals.

Overall, Medtronic reported strong financial results in Q3 2026, driven by key growth areas in cardiovascular and surgical technologies, while also navigating challenges in certain segments and external pressures from tariffs and competition. The company remains optimistic about its growth trajectory and strategic initiatives moving forward.

MDT — Medtronic plc